Drug intelligence / Profile preview

PB-015

Development stage: Preclinical
Lead developer: Polpharma Biologics

Overview

PB-015 is a biosimilar drug candidate developed by Polpharma Biologics for the treatment of cancers (neoplasms). It is classified as an antineoplastic agent, but its precise mechanism of action and reference/original biologic are not publicly disclosed. As of the latest updates, there has been no reported clinical development beyond preclinical or early research stages, and no active clinical trials or approvals have been identified. The drug is not considered a new molecular entity and does not have orphan drug status[1][2].

Other names: PB-015PB015PB 015

Beyond the preview

Go deeper on PB-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB-015.

Explore the full profile